The researchers used data collected from 2010 to 2016 through the North-West Child-Health-Integrated with Learning and Development longitudinal study. The same children were followed at three ages: Grade 1, when participants were 6–7 years old; Grade 4, when they were 9–10; and Grade 7, when they were 12–13. The cohort included 186 children classified as low SES and 147 as high SES, with boys and girls analyzed in each group. Undernutrition risk was assessed using height-for-age, weight-for-age, and body mass index-for-age, while overnutrition was assessed using body mass index-for-age, waist-to-height ratio, and body fat percentage.

Across Grades 1 to 7, low-SES children had a significantly higher risk of being at risk of stunting and underweight, with all reported p-values at or below 0.001. Their relative risk of classification as at risk of stunting was at least 178%, and the relative risk of being underweight was at least 259%. Conversely, low-SES children had lower measured prevalence of overweight or obesity by body mass index-for-age, waist-to-height ratio, and body fat percentage. The reported reductions in relative risk were at least 68% for waist-to-height ratio, at least 68% for body fat percentage, and at least 71% for body mass index-for-age, with all p-values at or below 0.003.

Some patterns changed during puberty. Stunting-risk prevalence increased by 24.1% among pubertal boys. Among pubertal girls, the higher risk of classification as at risk of stunting and the lower risk of overweight or obesity by body mass index-for-age each lost statistical significance over time. The abstract describes these results as indicating a population-level, but not individual-level, double burden of malnutrition, characterized by persistent undernutrition risk among low-SES children and greater overnutrition among high-SES children. Because the available evidence is the study abstract, it does not provide the full methods, detailed statistical estimates, or results needed to assess individual-level classification across all measures or the study’s wider limitations.

Subject of Research: Longitudinal differences in malnutrition measures by socioeconomic status among South African children aged 6 to 13

Article Title: Trajectories of the double burden of malnutrition and social inequality in 6–12-year-old South African children: The NW-child study

Article References: van Niekerk, E., Pienaar, A. E., & Monyeki, M. A. (2026). Trajectories of the double burden of malnutrition and social inequality in 6–12-year-old South African children: The NW-child study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07548-1

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07548-1

Keywords: child malnutrition, South Africa, longitudinal study, socioeconomic status, stunting, underweight, overweight, obesity, body composition, puberty, Trajectories, double

The scale of the dataset is what sets the study apart. Using random cluster sampling, the researchers enrolled 120,459 students from 15 junior and senior high schools spread across four districts and prefectures in Xinjiang, selected according to geographical distribution characteristics. Height and weight were measured in strict accordance with the Chinese National Student Physical Health Standard, and each participant was classified as underweight, normal weight, overweight, or obese based on body mass index, with a combined overweight-plus-obesity category also analyzed. Because the same surveillance framework ran every year from 2017 to 2021, the team could compare each pandemic-era year against a stable pre-pandemic baseline rather than relying on snapshots from unrelated surveys.

The headline finding is a sharp, statistically significant bump in body mass index in 2020. Mean BMI among the adolescents rose by 0.2 kilograms per square meter compared with previous years, an increase the authors describe as significant, before the trend reversed and declined in 2021. The statistical evidence for these shifts was robust: analysis of variance yielded an F statistic of 104.862 with a P value below 0.001, meaning the probability that such differences arose by chance is vanishingly small. A rise of 0.2 kg/m² may sound modest at the population level, but across hundreds of thousands of adolescents even small shifts in the BMI distribution can translate into large numbers of young people crossing clinical thresholds for overweight and obesity.

Those thresholds moved in exactly the worrying direction during the acute pandemic phase. Compared with the 2017 to 2019 baseline, the detection rate of underweight fell to 10.6 percent in 2020, while the overweight rate climbed to 9.5 percent and the combined overweight-and-obesity rate rose to 12.0 percent, with both increases statistically significant. In other words, the pandemic year did not simply make some adolescents heavier; it shifted the entire weight distribution, pulling teenagers away from the low end of the scale and pushing them toward the high end. The researchers used chi-squared tests to confirm that these changes in category prevalence were unlikely to be artifacts of sampling variation.

To quantify risk more precisely, the team turned to binary logistic regression, using 2017 as the reference year and accounting for the clustered sampling design. The results were striking. In 2020, the odds of being underweight dropped to 0.668 times the baseline odds, a 95 percent confidence interval of 0.633 to 0.706, while the odds of overweight rose to 1.280 times baseline, with a confidence interval of 1.199 to 1.366, and the odds of combined overweight and obesity rose to 1.364 times baseline, with a confidence interval of 1.286 to 1.448. Because those confidence intervals sit entirely above 1.0 for the excess-weight outcomes and entirely below 1.0 for underweight, the associations are statistically secure at the conventional 5 percent significance level the study adopted.

Then came the reversal. As China’s pandemic response entered its normalized prevention and control phase, with schools operating under routine rather than emergency conditions, the adolescent weight distribution began drifting back toward its pre-pandemic shape. In 2021, the underweight rate rebounded to 13.9 percent, while overweight and combined overweight-and-obesity rates fell to 8.0 percent and 10.7 percent respectively, all changes statistically significant compared with 2020. The regression models echoed this pattern: the odds of underweight in 2021 were 0.917 times the 2017 baseline, with a confidence interval of 0.872 to 0.965, and the odds of combined overweight and obesity fell to 1.201 times baseline, with a confidence interval of 1.131 to 1.275. The elevated risk had not vanished, but it was clearly receding.

One of the most consequential findings concerns who was affected most. The BMI changes were not uniform across the population: girls showed greater fluctuation than boys, with the analysis of variance producing F statistics of 114.950 and 30.063 for the two groups, both with P values below 0.001, and statistically significant differences appeared across all age groups as well. The recovery in 2021 was also more pronounced among girls and among the 13-to-15-year-old group, the younger half of the cohort. This gender and age patterning matters for intervention design, because it suggests that the pandemic’s metabolic impact was concentrated in specific subgroups rather than spread evenly, and that younger adolescents may be more resilient, or more responsive to restored routines, than older ones approaching the end of puberty.

Why would a year of pandemic restrictions push adolescents toward higher body weight? The study’s design does not test mechanisms directly, but the plausible pathways are well understood in the broader literature on childhood obesity. School closures curtail structured physical activity, including physical education classes, organized sports, and the incidental walking that a school day imposes. Lockdowns alter eating patterns, increasing snacking and reliance on energy-dense convenience foods while removing the regularity of school meal schedules. Screen time rises, sleep rhythms drift, and the psychological stress of isolation can itself promote weight gain. The simultaneous decline in underweight detection during 2020 is consistent with this picture: adolescents who might otherwise have remained lean gained weight, thinning out the low end of the distribution even as the high end expanded.

The partial reversal in 2021 is equally informative. It suggests that the pandemic’s effect on adolescent weight was not a permanent scar but a perturbation tied to the disruption of daily routines. When normalized prevention and control restored a measure of regularity to school life, the forces that had driven BMI upward weakened, and the distribution began to revert. The authors emphasize, however, that the return was incomplete: the 2021 odds of combined overweight and obesity remained 1.201 times the 2017 baseline, indicating a lingering elevation even as the acute impact faded. Whether the distribution would have fully normalized with more time is a question the study’s five-year window cannot answer definitively.

For public health planners, the study carries a clear message about vigilance and precision. The researchers conclude that the initial stage of the pandemic was associated with a significant negative impact on the weight status of Chinese adolescents, and they call for strengthened long-term dynamic monitoring of adolescent weight changes alongside precisely targeted health interventions to prevent undesirable physical status and promote healthy development. The subgroup findings point the way: interventions aimed at girls and at younger adolescents during periods of major routine disruption could yield outsized benefits. With adolescent obesity rising across much of the world, and with future pandemics or other large-scale disruptions a certainty rather than a hypothetical, the Xinjiang dataset offers something precious, a quantified, longitudinal record of how quickly a population of teenagers can shift toward excess weight when normal life stops, and how quickly the trend can bend back when it resumes.

Subject of Research: The impact of the COVID-19 pandemic and its normalized prevention and control phase on BMI and overweight and obesity prevalence among Chinese adolescents aged 13 to 18.

Article Title: A longitudinal study on differential impacts of the COVID-19 pandemic and normalized prevention and control on overweight and obese adolescents in China

Article References: Maitituersun, Y., Su, R., Yang, G., & Taerken, A. Y. (2026). A longitudinal study on differential impacts of the COVID-19 pandemic and normalized prevention and control on overweight and obese adolescents in China. BMC Pediatrics, 26(1), Article 882. https://doi.org/10.1186/s12887-026-07558-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07558-z

Keywords: COVID-19, adolescent health, obesity, overweight, body mass index, longitudinal study, China, Xinjiang, public health, school closures, pediatrics, weight status

The study, published in Frontiers in Animal Science, was led by Andrew Knight of Murdoch University, together with Alexander Bauer and Jenny L. Mace. The team conducted a cross-sectional online survey of companion animal carers, open from May to December 2020, which gathered information on the health of one resident cat per household that had lived there for at least a year. From a larger pool of 4,057 dog and cat carers, 1,397 cat carers met the inclusion criteria, and 1,305 cats were ultimately analysed across the two diet groups of interest: 1,178 cats, or 90.3 percent, fed conventional meat-based diets, and 127 cats, or 9.7 percent, fed vegan diets for at least one year. Carers reported the assessments of their primary veterinarians concerning the cats’ health over the previous twelve months.

The researchers focused on six body weight-related disorders: overweight, underweight, osteoarthritis or arthritis, intervertebral disc disease, other mobility disorders, and other musculoskeletal problems. According to the carer-reported veterinary assessments, only 3.1 percent of vegan-fed cats were classified as overweight, compared with 4.1 percent of meat-fed cats. In unadjusted statistical analyses, cats fed vegan diets had odds of being overweight that were 24 percent lower than their meat-fed counterparts. When the researchers adjusted for ten potential confounding variables, including age, sex, neuter status, activity level and a range of feeding practices, the difference widened to 34 percent lower odds of overweight in the vegan group.

Here is the crucial caveat: neither figure reached statistical significance. The confidence intervals were wide, spanning from a 73 percent reduction to a 116 percent increase in the unadjusted overweight analysis, reflecting the relatively small number of observed cases. Only four vegan-fed cats were classified as overweight at all. The authors interpreted the raw 24 percent effect as a “tendency” and the adjusted 34 percent effect as a “strong tendency,” using heuristic categories they established in earlier work on general health outcomes from the same survey. Following the American Statistical Association’s guidance on p-values, they emphasised effect strength over binary significance thresholds, but they are explicit that the findings should be treated as hypothesis-generating rather than confirmatory.

The pattern extended to underweight as well. Cats fed vegan diets showed 66 percent lower odds of being underweight in the unadjusted models, a difference the authors labelled a strong tendency, though again it was not statistically significant. More striking still were the secondary outcomes: not a single vegan-fed cat in the sample was reported to suffer from osteoarthritis or arthritis, intervertebral disc disease, other mobility disorders, or other musculoskeletal problems. Among the meat-fed group, 15 cats had arthritis impairing mobility, one had intervertebral disc disease, eight had other mobility problems and 14 had other musculoskeletal problems. Because zero cases occurred in the vegan group, the researchers could not run regression models for these outcomes at all, and the low prevalence likely reflects the small size of the vegan subgroup rather than any proven protective effect.

The statistical machinery behind the study was deliberately cautious. The analysis proceeded in three steps: a descriptive stage, an exploratory stage estimating the diet effect with ten separate one-variable regression models, and a final fully adjusted model restricted to outcomes with at least 50 cases across both diet groups, a criterion met only by overweight. That final model produced an area under the curve of 0.78 on a held-out test set, indicating acceptable fit. Two sensitivity analyses bolstered the findings: propensity score matching on age, which matters because vegan-fed cats averaged 6.2 years old versus 8.2 years for meat-fed cats, yielded broadly similar reductions of 21 percent in overweight and 50 percent in underweight odds. And when 64 raw-meat-fed cats were folded into the meat-based comparison group, the results barely moved, with the adjusted overweight effect shifting by just one percentage point.

Why might plant-based diets be associated with leaner cats? The authors cannot answer definitively, since they collected no compositional data, but they outline plausible mechanisms. Nutritional guidelines for weight management in cats favour lower calories, lower fat, higher fibre and higher L-carnitine content. Plant-derived ingredients often contain more fibre and potentially fewer calories or less fat than animal sources. More intriguingly, conventional cat foods are not required to guarantee L-carnitine, a vitamin-like amino acid derivative critical for energy metabolism and the retention of lean body tissue, because manufacturers assume meat supplies adequate quantities. Some nutritionally sound vegan cat foods, by contrast, are explicitly supplemented with L-carnitine, potentially offering cats greater protection against weight gain. There is also a paradox worth noting: vegan-fed cats in this sample were actually more often fed dry food and fed ad libitum, both factors previously associated with increased overweight risk, yet they still showed lower odds of excess weight.

The study also surfaced a striking discrepancy in how weight was judged. Veterinarians reportedly considered 94 percent of meat-fed cats and 96 percent of vegan-fed cats to be at ideal weight, while carers’ own opinions put those figures at 70 percent and 76 percent respectively. Usually the reverse is true, with owners less likely than vets to recognise overweight. The authors suggest several explanations: carer concern may capture perceived adiposity rather than clinically communicated problems; body condition scoring is under-recorded in practice, with a UK study of 129,076 cat visits finding weight recorded in only 10 percent of visits; and surveys may attract more health-conscious carers. The very low 4 percent veterinary-reported overweight prevalence in this sample contrasts sharply with estimates of 30 to 60 percent from veterinary-assessed studies, which may mean the study underestimated overweight overall, a limitation the authors acknowledge candidly.

That said, the limitations extend further. All outcomes relied on carer reports, introducing potential recall and reporting bias, and carer-reported assessments are not equivalent to standardised veterinary body condition scoring. Social desirability bias among vegan-feeding carers, possible confounding by unmeasured health-protective behaviours, and survivorship bias, in which cats harmed by vegan diets are switched back to meat and vanish from the vegan group, cannot be excluded. The analysis also excluded endocrine, urinary, cardiac and dermatological comorbidities of obesity. The fully adjusted model, with only four overweight events in the vegan group, fell short of the traditional ten-events-per-parameter rule of thumb for logistic regression.

What the study does deliver is a consistent direction of effect across every model the authors ran, a robustness to alternative analytical choices, and a clear roadmap for future work. Larger samples, prospective designs, direct extraction of veterinary-recorded body weights and standardised body condition scores, and measurement of actual diet composition and energy intake would all help resolve whether the leaner-cats pattern is real. For now, the message is nuanced: among these 1,305 cats, vegan-fed animals fared no worse on body weight and related disorders than meat-fed ones, and descriptively better, but nobody should yet conclude that vegan diets slim down cats. This is exploratory science, published transparently with its uncertainty on display, precisely so that the next generation of studies can test the hypothesis properly.

Subject of Research: The association between vegan versus meat-based diets and body weight-related disorders in domestic cats

Article Title: Impacts of a vegan diet on body weight and related health disorders in 1,305 cats: an exploratory cross-sectional survey

Article References: Knight, A., Bauer, A., & Mace, J. L. (2026). Impacts of a vegan diet on body weight and related health disorders in 1,305 cats: an exploratory cross-sectional survey. Frontiers in Animal Science, 7, Article 1939965. https://doi.org/10.3389/fanim.2026.1939965

Image Credits: AI Generated

DOI: 10.3389/fanim.2026.1939965

Keywords: cats, vegan cat food, feline obesity, overweight, body condition score, pet nutrition, veterinary epidemiology, cross-sectional survey, logistic regression, obligate carnivores, L-carnitine, pet health

To understand why inflammation matters so much in this context, it helps to revisit what adipose tissue actually does. Far from being a passive energy depot, fat tissue is an active endocrine organ. In obesity, enlarged and stressed adipocytes begin releasing pro-inflammatory signaling molecules, including tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1, while macrophages infiltrate the tissue and amplify the inflammatory cascade. This chronic, systemic low-grade inflammation is now recognized as a central driver of insulin resistance, atherosclerosis, and cardiometabolic risk. Because of this, researchers have long suspected that effective weight-loss therapies might deliver a double payoff: direct metabolic improvement and a measurable cooling of the inflammatory state. The new meta-analysis puts that hypothesis to a rigorous test for one of the most consequential weight-loss drugs on the market.

Semaglutide works by mimicking glucagon-like peptide-1, a gut-derived incretin hormone that the body releases after meals. By binding to and activating the GLP-1 receptor, the drug slows gastric emptying, enhances the sensation of satiety in the brain, and reduces appetite, all of which lead to a sustained caloric deficit. Approved initially for type 2 diabetes and later for chronic weight management, semaglutide has demonstrated some of the largest pharmacological weight reductions ever recorded in obesity trials. But GLP-1 receptors are not confined to the pancreas, gut, and hypothalamus; they are also expressed on immune cells, including macrophages, which has led to speculation that the drug might dampen inflammation both indirectly, through weight loss itself, and directly, through receptor-mediated effects on immune signaling pathways.

Disentangling those two mechanisms is precisely what makes a systematic review and meta-analysis valuable. Individual trials of semaglutide in people without diabetes have typically been powered to detect weight change, not shifts in circulating inflammatory markers, so single studies often report inconclusive or heterogeneous results on inflammation. By aggregating data across trials, the authors of the new analysis could extract a clearer signal, quantifying the average effect of subcutaneous semaglutide on body weight and on key inflammatory biomarkers—most notably high-sensitivity C-reactive protein, the liver-produced sentinel molecule that rises in response to systemic inflammation and is one of the most robust predictors of cardiovascular events in observational studies.

The population under scrutiny is also worth emphasizing. Most of the early evidence for semaglutide’s metabolic benefits came from trials that enrolled people with type 2 diabetes, leaving open the question of whether the drug’s metabolic and anti-inflammatory effects apply to the much larger population of adults with overweight or obesity who have never developed diabetes. The trials included in this review focused specifically on that non-diabetic group, which matters because their baseline metabolism differs in important ways: insulin secretion is generally more preserved, beta-cell function is more intact, and the drivers of their inflammation are more closely tied to adiposity itself than to diabetic dysglycemia. Any anti-inflammatory benefit seen in this population is therefore more likely attributable to the drug’s effects on fat mass and appetite regulation rather than to improved glucose control.

The findings, synthesized across the pooled trials, support the picture that has emerged from the landmark semaglutide weight-management program: substantial and clinically meaningful weight reduction in adults treated with the medication compared with placebo. Equally significant, the analysis evaluated changes in inflammatory markers alongside the weight outcomes, addressing whether the drug’s metabolic benefits are accompanied by reductions in the molecular signatures of chronic inflammation. This paired assessment is important for clinicians, because cardiovascular guidelines increasingly treat inflammation as a therapeutic target in its own right. If a weight-loss drug reliably lowers both body weight and C-reactive protein, its case as a preventive intervention becomes considerably stronger than if it merely changes a number on the scale.

For readers following the cultural moment around GLP-1 drugs, the scientific stakes of analyses like this one are hard to overstate. Semaglutide and related incretin therapies have moved from diabetes clinics into mainstream medicine at extraordinary speed, and demand has at times outstripped supply. Health systems are now grappling with questions about which patients should receive these medications, how long treatment should continue, and what the long-term benefits and risks are. Evidence connecting semaglutide to reduced inflammation in people without diabetes feeds directly into those deliberations, because it suggests the drug may address a broader swath of obesity-related pathology than weight loss alone would predict, potentially altering trajectories of cardiovascular and inflammatory disease in a patient population that has historically had limited pharmacological options.

At the same time, the authors and observers of this evidence base caution that meta-analyses inherit the limitations of the trials they aggregate. The number of trials reporting inflammatory markers in non-diabetic populations remains relatively modest, follow-up durations in weight-management trials are typically measured in months rather than years, and the standardization of inflammatory marker assays can vary between studies. Weight loss itself, achieved by any means—diet, exercise, or surgery—is known to reduce C-reactive protein and other inflammatory markers, so a central interpretive question is how much of the anti-inflammatory effect reflects the magnitude of weight reduction versus a direct pharmacological action on immune cells. The meta-analytic framework allows researchers to begin teasing these contributions apart, but definitive answers will require dedicated trials with inflammation as a primary endpoint and longer observation windows.

Those caveats notwithstanding, the broader trajectory of the evidence is coherent. Across diabetes and non-diabetes populations alike, GLP-1 receptor agonism is emerging as a lever that moves multiple cardiometabolic dials simultaneously: appetite, body weight, glycemia where relevant, and systemic inflammation. Large cardiovascular outcomes trials of semaglutide in high-risk populations have already demonstrated reductions in major adverse cardiovascular events, and mechanistic work suggests that attenuation of vascular and adipose inflammation may be part of the explanation. The new review in the International Journal of Obesity extends this logic to adults with overweight or obesity without diabetes, the very population in which preventive cardiology has the most room to intervene before disease becomes established.

What comes next is likely to be a decade of refinement. Researchers are now designing studies to identify which patients respond best to incretin-based therapies, to determine how inflammatory marker changes translate into hard clinical outcomes, and to establish how long treatment must continue to sustain both weight loss and the anti-inflammatory state it appears to accompany. For the millions of adults living with obesity who do not have diabetes, the accumulating evidence offers a shift in how these drugs are understood: not simply appetite suppressants, but agents that appear to reach into the inflammatory biology that makes excess weight dangerous in the first place. As pooled analyses like this one accumulate, they will help clinicians and patients weigh semaglutide’s benefits with sharper precision—and they underscore how much modern obesity medicine has evolved from a focus on willpower to a rigorous science of hormones, receptors, and immune signaling.

Subject of Research: Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes

Article Title: Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis

Article References: Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02189-x

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02189-x

Keywords: semaglutide, obesity, weight loss, inflammatory markers, GLP-1 receptor agonist, systematic review, meta-analysis, C-reactive protein, International Journal of Obesity, overweight, non-diabetic adults, cardiometabolic health

The numbers behind the review are stark. The latest National Health and Morbidity Survey, conducted in 2023, recorded an adult overweight and obesity prevalence of 54.4 percent, placing Malaysia second highest among Association of Southeast Asian Nations members. When the threshold is lowered to a body mass index of 23 kilograms per square metre, the cut-off increasingly considered appropriate for Asian populations, the proportion of adults at risk climbs to roughly 70 percent. Globally, obesity affected 38 percent of adults in 2020 and is projected to exceed half the world’s population by 2035, making Malaysia a case study in how rapidly middle-income nations are absorbing the metabolic consequences of nutritional transition.

The research team, led by Quan-Hziung Lim and colleagues, conducted a structured search across Web of Science, PubMed and Google Scholar, screening 3626 articles before settling on the final 179. The majority of these studies, nearly 70 percent, addressed the epidemiology of obesity, while fewer than 9 percent focused on developing new treatment modalities. Most relied on community-sampled data rather than nationally representative surveys, and the overwhelming majority were cross-sectional in design. Although randomised controlled trials increased from just three in the previous decade to 25 in the current one, most lasted less than a year, and longitudinal cohorts and pragmatic real-world trials remain scarce. This pattern, the authors note, closely mirrors the findings of an earlier scoping review covering 2008 to 2017, suggesting that the methodological profile of Malaysian obesity research has shifted only modestly over time.

One of the most consequential themes to emerge concerns how obesity itself should be measured. Malaysian studies consistently demonstrate that metabolic risk emerges well below conventional body mass index thresholds. Women with normal BMI but elevated body fat percentage, so-called normal-weight obese individuals, showed substantially higher odds of abdominal obesity, hypertriglyceridemia and hypertension. From a BMI of 23 onward, associations with undiagnosed diabetes, high blood pressure and elevated cholesterol become firmly established, and refined analyses suggest optimal hypertension prediction thresholds of around 23 kilograms per square metre for men and 24 for women. Meanwhile, waist-to-height ratio above approximately 0.5 repeatedly outperformed BMI in predicting excess adiposity and cardiometabolic disease, leading the authors to argue that a dual measurement strategy combining BMI with abdominal measures offers a pragmatic, low-cost route to earlier detection.

The review also documents a paradox familiar from international literature: in a large retrospective cohort, overweight individuals had lower all-cause mortality than those in the normal range, yet overweight and obesity contributed 7 percent of the national cancer burden, second only to tobacco smoking. Above a BMI of 30, more than three-quarters of Malaysians with obesity already carry at least one metabolic complication, and the probability of transitioning from metabolically healthy to unhealthy obesity rises by 4.4 percent with each passing year. Severe obesity at or above 35 kilograms per square metre conferred excess cardiovascular mortality for the population overall. Psychosocial evidence, though thinner, points to elevated rates of depression among people with obesity, with healthcare workers who reported depression showing double the odds of obesity, and pandemic-era surveys linking overweight status to mild-to-severe depressive symptoms.

Predisposition patterns are equally revealing. Malaysian women consistently show higher rates and risks of obesity than men, with 33 to 64 percent greater odds, and steeper increases in BMI and waist circumference with age. Prevalence peaks in middle age and declines in older adults, though the authors caution this may reflect survivorship bias rather than genuine protection. Ethnic disparities are pronounced, with Malay, Indian and other Bumiputera groups showing consistently higher odds of overweight and obesity compared with Chinese Malaysians, a pattern echoed in neighbouring Singapore. Genetic research remains exploratory, identifying variants in genes such as LEPR, ADIPOQ and FTO among local populations, but with limited immediate clinical applicability. More actionable are occupational findings: night-shift work doubled the risk of metabolic syndrome among manufacturing workers, and nurses showed particularly elevated obesity rates.

Dietary drivers form a third major thread. A quasi-historical analysis linked Malaysia’s rising obesity to a 30 percent caloric oversupply, with shifts toward wheat, sugar, meat and animal-based protein. Across multiple studies, excess intake of protein, meat, sugar, sodium and ultra-processed foods, combined with inadequate consumption of fruits, vegetables and fibre, was consistently associated with higher obesity risk. Emerging chrononutrition research suggests that meal timing matters, with late-day energy and carbohydrate intake increasing metabolic risk among people with obesity. On the policy front, the picture is sobering: four years after its introduction, nearly 80 percent of Malaysians remained unaware of the Malaysian Healthy Plate messaging concept, healthy diets remain costly, and food insecurity among rural women was paradoxically linked with higher obesity rates.

Interventional research offers cautious grounds for optimism. Twenty-two community-based lifestyle studies were reviewed, ranging from pedometer-based walking programmes to combined diet and exercise packages. The government-initiated MyBFF@home programme for urban housewives produced modest but significant reductions in weight, BMI and visceral fat at six months, though sustainability at twelve months was variable. A structured face-to-face workplace programme achieved 7 percent weight loss, substantially outperforming an online equivalent, while group-based approaches were more effective than individual counselling. Notably, 91 percent of interventions operated at the micro level, targeting individual behaviour, with almost no macro-level policy interventions tested. Modelling work suggests that meaningful weight loss through physical activity alone requires roughly 1500 MET-minutes per week, equivalent to six to seven hours of moderate activity, a bar that nearly half of sedentary Malaysians are unlikely to clear without dietary change.

Clinical treatment presents a mixed frontier. Most approved obesity medications, including newer incretin-based therapies such as semaglutide and tirzepatide, are available in Malaysia, but monthly out-of-pocket costs of 800 to 1800 ringgit are prohibitive against a median monthly income of roughly 2800 ringgit, and only about 10 percent of people with obesity are ever offered pharmacotherapy. Metabolic and bariatric surgery has expanded rapidly since 1996, with procedures more than doubling between 2010 and 2016, delivering substantial weight loss and metabolic improvement at costs between 11,000 and 30,000 ringgit. Barriers persist on both sides of the consultation: patients report weight stigma, self-blame and misperception of their own weight status, while clinicians cite time constraints and limited training. The authors conclude that Malaysia stands at a critical inflection point, requiring coordinated, whole-of-society action, stronger longitudinal and policy research, and equitable access to effective therapies to prevent the deepening of a Stage 3 obesity profile in which the burden concentrates among the poorest.

Subject of Research: Mapping and narrative review of adult overweight and obesity research in Malaysia from 2015 to 2024

Article Title: The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review

Article References: Lim, Q.-H., Khoo, J.-K., Ooi, Y.-G., Ramachandaram, A., & Ratnasingam, J. (2026). The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. The Lancet Regional Health – Western Pacific, 74, Article 101963. https://doi.org/10.1016/j.lanwpc.2026.101963

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101963

Keywords: obesity, Malaysia, overweight, body mass index, waist-to-height ratio, public health, nutrition transition, lifestyle intervention, bariatric surgery, GLP-1 receptor agonists, National Health and Morbidity Survey, noncommunicable diseases